Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2011 pubmed 30 citations

VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin.

Rossini. Lara L; Hashimoto. Yuichi Y; Suzuki. Hiroaki H; Kurita. Megumi M; Gianfriddo. Marco M; Scali. Carla C; Roncarati. Renza R; Franceschini. Davide D; Pollio. Giuseppe G; Trabalzini. Lorenza L; Terstappen. Georg C GC; Matsuoka. Masaaki M; Caricasole. Andrea A

Key Findings

  • VSTM2L directly binds Humanin in yeast and mammalian cells
  • VSTM2L is secreted, present in serum, and selectively expressed in the central nervous system
  • VSTM2L acts as a strong antagonist, diminishing Humanin’s neuroprotective effects in bioassays

Practical Outcomes

  • If you use Humanin supplements, be aware that your body may produce VSTM2L, which could limit its effectiveness. Future approaches might look at ways to lower VSTM2L levels or time Humanin dosing to avoid its antagonism, but no specific protocol changes are recommended yet.

Summary

Scientists discovered a protein called VSTM2L that sticks to the anti‑aging peptide Humanin and blocks its brain‑protective actions. This natural blocker is found in the blood and brain, meaning it could reduce the benefits of taking Humanin as a supplement.

Abstract

Humanin (HN) is a 24-residue peptide displaying a protective activity in vitro against a range of cytotoxic and neurotoxic insults, as well as mediating in vivo amelioration of Alzheimer disease (AD)-related memory impairment in experimental models. Published evidence suggests that the mechanisms through which HN exerts its cyto- and neuroprotective activity may include its secretion and binding to membrane-associated receptors. Here, we describe the identification of a new modulator of HN neuroprotective activity, V-set and transmembrane domain containing 2 like (VSTM2L), previously known as C20orf102. VSTM2L interacts with HN in both yeast and mammalian cells, is secreted in cultured cells, is present in serum, and is selectively expressed in the central nervous system. VSTM2L colocalizes with HN in distinct brain areas as well as in primary cultured neurons, where it plays a role in the modulation of neuronal viability. When tested in HN neuroprotection bioassays, VSTM2L acts as a strong antagonist of HN neuroprotective activity. In summary, VSTM2L is the first example of a secreted antagonist of HN and may play a role in the modulation of HN biological functions.

Study Information

Provider

pubmed

Year

2011

Date

2011-03-10T00:00:00.000Z

DOI

10.1096/fj.10-163535

Citations

30

References

46